Liveyon Pure Cast – Stem Cells APPROVED Internationally (E11)

For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

Episode 11 – Liveyon Pure Cast – Stem Cells APPROVED Internationally

Dr. Alan Gaveck: Welcome back to the Liveyon Pure Cast podcast. I’m Dr. Alan Gaveck, Director of Medical Education and Clinical Application at
Liveyon. And, of course, next to me is Dr. …or John Kosolcharoen.

J. Kosolcharoen: Doctor John.

Dr. Alan Gaveck: Doctor John. CEO and founder of Liveyon. John, how are you?

J. Kosolcharoen: I’m not actually a doctor, but I play one on TV, or at least on the Pure Cast once in a while.

Dr. Alan Gaveck: So, John, a lot of the stuff that … A lot of what you spend your time on is actually outside of the country.

J. Kosolcharoen: International development. Yeah. I mean, this last two weeks was a long one.

Dr. Alan Gaveck: And it’s actually … It’s good because a lot of people don’t realize rules in the United States are different than they are
in other parts of the world.

J. Kosolcharoen: For manufacturers, especially, big time.

Dr. Alan Gaveck: Well, not only that, I mean, not only just in the United States, but every country has their own kind of set of rules, don’t

J. Kosolcharoen: They do, yeah.

Dr. Alan Gaveck: So you’ve been working a lot international. And what’s the draw internationally?

J. Kosolcharoen: The international market … You know, I’m developing all of South America. So, I met with [AnnMatt] last week [inaudible
00:01:12], which are basically the FDA and the version of the import export biologics division to get … You know, so when
we’re looking to open up a country, the first thing we need to do is get an import/export license to export our stuff into
their country and import license to import it in, a tissue bank license to build to be able to store tissue, a distribution
license to be able to sell cells and tissues, and then we need to find out what the regulations are for doctors to be able to
treat patients. So I went and did that.

Dr. Alan Gaveck: So let’s take it from a point of view of what we do know. We are up and running in Costa Rica, right? What’s the big draw
there? What everybody looking for?

J. Kosolcharoen: Well, with all these countries? I mean, the big draw is the fact that we’re not limited to non-systemic use. So, for example,
in Cancun, if you have an autoimmune disease, if you have Parkinson’s, ALS, autism, fibromyalgia, gout, osteoarthritis,
rheumatoid arthritis, you can actually go to our facility in Mexico and get treated systemically through an IV and do
treatments down there that you cannot do here in the United States. Same product. It’s just a different application. I mean,
here in the United States we do joint injections, outside of the country.

So there’s actually five different treatment modalities. Two of them are very similar, but actually very different. We have
cardiac pulmonary, which deals with all myocardial infarction and CLPD and lungs. We have neuro, skeletal or spine injuries,
diabetic neuropathy. And then we have aesthetics and anti-aging. So anti-aging is your cellular health and your cellular age.

Dr. Alan Gaveck: Internally.

J. Kosolcharoen: Internally. And aesthetics is how you look externally. So Costa Rica, our big focus there is aesthetics, anti-aging,

Dr. Alan Gaveck: You know, internationally the largest use of umbilical cord blood stem cell are for the treatment of autoimmune disorders.

J. Kosolcharoen: Yeah, that’d be our Cancun facility.

Dr. Alan Gaveck: When … You think that’s ever going to come to the United States?

J. Kosolcharoen: It’s going to be very, very slow and a very, very long time. I think that we’ll probably treat most of the world before
anything gets done here in the United States. I think that, I didn’t know if you want to go here, but if you do, I think that
the FDA really is looking to suppress what goes on here in the United States, primarily because, you know, Big Pharma has a
big hand in the bot.

Dr. Alan Gaveck: That’s kind of the direction I was going.

J. Kosolcharoen: Yeah.

Dr. Alan Gaveck: I mean, we see around the world where these tremendous things are happening and people are having to spend tons of money to
go there. Even if you’re just talking Panama.

J. Kosolcharoen: Look at when we went to Morocco and we spoke in Rabat and Casablanca. The guys that we met there that are in Malaysia,
Singapore, Korea, Thailand, and we’ll be in the Philippines, and we’re in Vietnam, or our center just opened in Vietnam.

Dr. Alan Gaveck: Right.

J. Kosolcharoen: The retail store distribution center just opened there. We’re doing trainings and seminars in the Philippines this summer.
Spain, Buenos Aires.

Dr. Alan Gaveck: There are 12, 12 around the world and 24 in the United States, something like that?

J. Kosolcharoen: Something like that.

Dr. Alan Gaveck: So it’s a big number. So it’s keeping you busy? Internationals keeping you busy?

J. Kosolcharoen: Yeah, it’s keeping my frequent flyer card miles all jacked up.

Dr. Alan Gaveck: But it’s also, you know, keeping you busy in the United States because we have a booming, growing business here.

J. Kosolcharoen: Yeah. I mean, we’ve been really boosting up our manufacturing. We just opened up the second clean room at Liveyon Labs to be
able to keep up with international volume. And Mexico and Costa Rica right now are really the leaders. Next week I’m going to
China. I’ll be in Shenzen Chenzhou, the Hanan island and [Hahu 00:05:20], and Hong Kong. So there’s four labs that are built
there. I’m partnering with a big company over there that’ll allow me to just go into the lab, bring our technology to access
the China market. But again, these are autoimmune disease and anti-aging treatments that people from around the world can
come, and if they have some type of autoimmune disease or something that can’t be treated here, or if they just really want
to be and feel younger internally and look better, then we have the center in Costa Rica.

Dr. Alan Gaveck: So basically they can reach out to Liveyon if they have questions.

J. Kosolcharoen: Yeah, they can go on

Dr. Alan Gaveck: And so if they have any questions about possibly where they could have anti-aging or cardiopulmonary or
that sort of thing done.

J. Kosolcharoen: Right.

Dr. Alan Gaveck: All right. Perfect, man. Good to have you back in town.

J. Kosolcharoen: Yeah, thanks.

Dr. Alan Gaveck: Stay around for a while?

J. Kosolcharoen: A week.

Dr. Alan Gaveck: A whole week. All right, good.

J. Kosolcharoen: Actually, tomorrow morning Jeff Hayes is coming. He’s going to film part of his –

Dr. Alan Gaveck: Big filmmaker.

J. Kosolcharoen: Yeah, big time filmmaker. He did Christ Revealed, he did The Healing Miracle. So he’s doing another stem cell docuseries, and
I had lunch with him two weeks ago when we had that charity event for the kids at [WATTS 00:00:06:30].

Dr. Alan Gaveck: Correct.

J. Kosolcharoen: And he had come by the lab and said like, “Wow, can I tape here and show your lab? It’s beautiful.” So they’re coming
tomorrow to show what a lab should look like for regenerative medicine. So it’d be good to see him tomorrow.

Dr. Alan Gaveck: Well, we were honored to be in their first one.

J. Kosolcharoen: Yup.

Dr. Alan Gaveck: Right? The Stem Cell miracle. All right. Beautiful. Stay in touch. Talk to you soon.

J. Kosolcharoen: All right, thanks.

Dr. Alan Gaveck: Bye, man.



Medical Professional Viewing Only (Disclaimer)</font color>

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.